LipoCure
LipoCure is developing highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading and drug-release mechanisms. Their platform technology enhances drug delivery, improves therapeutic efficacy, and reduces side effects for treatments of inflammatory diseases, infections, and cancers. Founded by Professor Barenholz, co-developer of Doxil®, LipoCure aims to bring more effective and safer therapies through innovative liposomal drug delivery systems.
Industries
Nr. of Employees
small (1-50)
LipoCure
Hadassah Ein Kerem Campus, Biotechnology Park Jerusalem, POB 12235 Israel 91120
Products
LC-100
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-200
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-300
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-400
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-100
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-200
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-300
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
LC-400
Pipeline candidate listed on the company's pipeline pages; no technical details provided on the referenced page.
Expertise Areas
- Liposomal drug delivery
- Nanomedicine formulation
- Targeted drug delivery (passive/EPR-based)
- Drug loading and controlled release
Key Technologies
- Liposome-based nanoparticle formulations
- Remote/active drug loading into liposomes
- Controlled/triggered release mechanisms
- Enhanced permeability and retention (EPR) targeting